Skip to content

Study · Randomized controlled trial · n = 199 · 1984

11 results

Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

The source lists no authors.

The New England journal of medicine1 Nov 1984Cited by 395 (Europe PMC)

PMID6436700 (opens in a new tab)DOI10.1056/nejm198411153112004 (opens in a new tab)PepBankPUB-06436700
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic prostate cancer, testosterone and dihydrotestosterone suppression and acid phosphatase decreases were comparable with leuprolide and DES.

    In plain wordsIn patients with metastatic prostate cancer, leuprolide and DES produced comparable testosterone, dihydrotestosterone and acid phosphatase responses.

    Peptide
    Leuprolide
    Outcome
    No significant changeTestosterone, dihydrotestosterone and acid phosphatase responses
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Biochemical response · Endocrine and hormones
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Suppression of testosterone and dihydrotestosterone and decreases in acid phosphatase were comparable in the two groups.
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with metastatic prostate cancer, painful gynecomastia was less frequent with leuprolide than DES (P less than 0.00001).

    In plain wordsIn patients with metastatic prostate cancer, painful breast enlargement was less frequent with leuprolide than DES.

    Peptide
    Leuprolide
    Outcome
    DecreasePainful gynecomastia
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Adverse events · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients receiving DES experienced more frequent painful gynecomastia (P less than 0.00001), nausea and vomiting (P = 0.02), edema (P = 0.008), and thromboembolism (P = 0.065) than those receiving leuprolide.
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with metastatic prostate cancer, nausea and vomiting were less frequent with leuprolide than DES (P = 0.02).

    In plain wordsIn patients with metastatic prostate cancer, nausea and vomiting were less frequent with leuprolide than DES.

    Peptide
    Leuprolide
    Outcome
    DecreaseNausea and vomiting
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Gastrointestinal adverse events · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients receiving DES experienced more frequent painful gynecomastia (P less than 0.00001), nausea and vomiting (P = 0.02), edema (P = 0.008), and thromboembolism (P = 0.065) than those receiving leuprolide.
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with metastatic prostate cancer, edema was less frequent with leuprolide than DES (P = 0.008).

    In plain wordsIn patients with metastatic prostate cancer, swelling was less frequent with leuprolide than DES.

    Peptide
    Leuprolide
    Outcome
    DecreaseEdema
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Adverse events · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients receiving DES experienced more frequent painful gynecomastia (P less than 0.00001), nausea and vomiting (P = 0.02), edema (P = 0.008), and thromboembolism (P = 0.065) than those receiving leuprolide.
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with metastatic prostate cancer, thromboembolism was less frequent with leuprolide than DES (P = 0.065).

    In plain wordsIn patients with metastatic prostate cancer, blood clots were less frequent with leuprolide than DES, with P = 0.065.

    Peptide
    Leuprolide
    Outcome
    DecreaseThromboembolism
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Adverse events · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Patients receiving DES experienced more frequent painful gynecomastia (P less than 0.00001), nausea and vomiting (P = 0.02), edema (P = 0.008), and thromboembolism (P = 0.065) than those receiving leuprolide.
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with metastatic prostate cancer, hot flashes were more frequent with leuprolide than DES (P = 0.00001).

    In plain wordsIn patients with metastatic prostate cancer, hot flashes were more frequent with leuprolide than DES.

    Peptide
    Leuprolide
    Outcome
    IncreaseHot flashes
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Adverse events · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The leuprolide group reported more "hot flashes" (P = 0.00001).
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic prostate cancer, objective response occurred in 86% with leuprolide versus 85% with DES.

    In plain wordsIn patients with metastatic prostate cancer, objective response occurred in 86% with leuprolide and 85% with DES.

    Peptide
    Leuprolide
    Outcome
    IncreaseOverall objective response
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Measurements

    Objective response
    86%
    leuprolide
    Objective response
    85%
    DES

    Source sentences

    Summary
    Overall, 86 per cent of the leuprolide group had an objective response (complete response, 1 per cent; partial response, 37 per cent; stable disease, 48 per cent), as compared with 85 per cent of the DES group (complete, 2 per cent; partial, 44 per cent; stable, 39 per cent).
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic prostate cancer, complete response occurred in 1% with leuprolide versus 2% with DES.

    In plain wordsIn patients with metastatic prostate cancer, complete response occurred in 1% with leuprolide and 2% with DES.

    Peptide
    Leuprolide
    Outcome
    DecreaseComplete response
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Measurements

    Complete response
    1%
    leuprolide
    Complete response
    2%
    DES

    Source sentences

    Summary
    Overall, 86 per cent of the leuprolide group had an objective response (complete response, 1 per cent; partial response, 37 per cent; stable disease, 48 per cent), as compared with 85 per cent of the DES group (complete, 2 per cent; partial, 44 per cent; stable, 39 per cent).
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic prostate cancer, partial response occurred in 37% with leuprolide versus 44% with DES.

    In plain wordsIn patients with metastatic prostate cancer, partial response occurred in 37% with leuprolide and 44% with DES.

    Peptide
    Leuprolide
    Outcome
    DecreasePartial response
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Measurements

    Partial response
    37%
    leuprolide
    Partial response
    44%
    DES

    Source sentences

    Summary
    Overall, 86 per cent of the leuprolide group had an objective response (complete response, 1 per cent; partial response, 37 per cent; stable disease, 48 per cent), as compared with 85 per cent of the DES group (complete, 2 per cent; partial, 44 per cent; stable, 39 per cent).
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic prostate cancer, stable disease occurred in 48% with leuprolide versus 39% with DES.

    In plain wordsIn patients with metastatic prostate cancer, stable disease occurred in 48% with leuprolide and 39% with DES.

    Peptide
    Leuprolide
    Outcome
    IncreaseStable disease
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Measurements

    Stable disease
    48%
    leuprolide
    Stable disease
    39%
    DES

    Source sentences

    Summary
    Overall, 86 per cent of the leuprolide group had an objective response (complete response, 1 per cent; partial response, 37 per cent; stable disease, 48 per cent), as compared with 85 per cent of the DES group (complete, 2 per cent; partial, 44 per cent; stable, 39 per cent).
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic prostate cancer, one-year survival was 87% with leuprolide versus 78% with DES (P = 0.17).

    In plain wordsIn patients with metastatic prostate cancer, one-year survival was 87% with leuprolide and 78% with DES, with P = 0.17.

    Peptide
    Leuprolide
    Outcome
    IncreaseOne-year survival
    Study

    n = 199

    Comparator
    DES 3 mg daily
    Outcome group
    Mortality · Cancer
    Studied dose
    1 mg daily · subcutaneousAs given in this study (human).

    Measurements

    Survival
    87%
    leuprolide at one year
    Survival
    78%
    DES at one year

    Source sentences

    Summary
    Actual survival rates at one year were 87 per cent for the leuprolide group and 78 per cent for the DES group (P = 0.17).
    2 context sentences
    Summary · context
    We compared the efficacy and safety of the gonadotropin-releasing hormone analogue, leuprolide (1 mg subcutaneously daily), with diethylstilbestrol (DES, 3 mg by mouth daily) in patients with prostate cancer and distant metastases (Stage D2) who had not previously received systemic treatment.
    Summary · context
    Ninety-eight patients were randomly assigned to leuprolide, and 101 to DES.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.